Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders. | ClinicLens

Background/Objectives: Functional bowel disorders (FBDs) are chronic gastrointestinal conditions that substantially impair quality of life. This randomized, double-blind, placebo-controlled trial investigated the effects of Heyndrickxia coagulans IDCC 1201 (COA 1201) in adults wi

Medical Literature · Updated 2026-08-17

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.